We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00374530
First Posted: September 11, 2006
Last Update Posted: August 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Danish Headache Center
  Purpose
Before, during and after intravenous administration of PGE2 we score/measure headache, rCBF, blood flow in the middle cerebral artery and diameter of superficial temporal artery and correlate that to known pathophysiology of headache to see if PGE2 is involved in headache pathophysiology.

Condition Intervention
Headache Migraine Drug: PGE2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Official Title: Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2

Resource links provided by NLM:


Further study details as provided by Danish Headache Center:

Primary Outcome Measures:
  • Headache

Secondary Outcome Measures:
  • rCBF, blood flow, diameter of STA/RA, HR, BP

Estimated Enrollment: 12
Study Start Date: August 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers

Exclusion Criteria:

  • Primary Headache, headache on the day of the investigation, hypertension, hypotension, pregnant/nursing, daily intake of medication (except oral contraceptives), Cardiovascular or CNS disease, drug/alcohol abuse, psychiatric disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00374530


Locations
Denmark
Danish Headache Center
Glostrup, Denmark, DK-2600
Sponsors and Collaborators
Danish Headache Center
Investigators
Principal Investigator: Troels Wienecke, MD Danish Headache Center
  More Information

ClinicalTrials.gov Identifier: NCT00374530     History of Changes
Other Study ID Numbers: KA-20060026
First Submitted: September 8, 2006
First Posted: September 11, 2006
Last Update Posted: August 1, 2007
Last Verified: July 2007

Additional relevant MeSH terms:
Headache
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Dinoprostone
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs